

1 **Pediatric SARS-CoV-2 seroprevalence in Arkansas over the**
2 **first year of the COVID-19 pandemic**

3
4 Karl W. Boehme, PhD^{1,2,3#}, Joshua L. Kennedy, MD^{4,5,6,#}, Jessica Snowden, MD⁴, Shana M.
5 Owens, PhD¹, Marianne Kouassi, BS¹, Ryan L. Mann, BS¹, Amairani Paredes, BS¹, Claire Putt,
6 BA⁴, Laura James, MD⁴, Jing Jin, MPH⁷, Ruofei Du, PhD⁷, Catherine Kirkpatrick, BS⁶, Zeel
7 Modi, BA⁵, Katherine Caid, BS⁵, Namvar Zohoori, MD, MPH, PhD^{7,8}, Atul Kothari, MD^{5,8,9},
8 Bobby L. Boyanton, Jr., MD¹⁰, and J. Craig Forrest, PhD^{1,2,3}

9
10 ¹ Department of Microbiology & Immunology, College of Medicine, University of Arkansas for
11 Medical Sciences, Little Rock, AR

12 ² Center for Microbial Pathogenesis and Host Inflammatory Responses, University of Arkansas
13 for Medical Sciences, Little Rock, AR

14 ³ Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little
15 Rock, AR

16 ⁴ Department of Pediatrics, College of Medicine, University of Arkansas for Medical Sciences,
17 Little Rock, AR

18 ⁵ Department of Internal Medicine, College of Medicine, University of Arkansas for Medical
19 Sciences, Little Rock, AR

20 ⁶ Arkansas Children's Research Institute, Little Rock, AR.

21 ⁷ Department of Biostatistics, College of Public Health, University of Arkansas for Medical
22 Sciences, Little Rock, AR

23 ⁸ Arkansas Department of Health, Little Rock, AR.

24 ⁹ Department of Bioinformatics, College of Medicine, University of Arkansas for Medical
25 Sciences, Little Rock, AR

26 ¹⁰ Departments of Pathology, Arkansas Children's Hospital and University of Arkansas for
27 Medical Sciences, Little Rock, AR

28
29 #These authors contributed equally to the work.

30
31 Running Title: Pediatric SARS-CoV-2 seroprevalence in Arkansas

32

33 **FOOTNOTES**

34 ‡ **Corresponding authors:**

35 Karl W. Boehme

36 Mailing address: 4301 W. Markham Dr. #511, Little Rock, AR 72205

37 Phone: (501) 686-5189

38 Email: kwboehme@uams.edu

39

40 J. Craig Forrest

41 Mailing address: 4301 W. Markham Dr. #511, Little Rock, AR 72205

42 Phone: (501)

43 Email: jcforrest@uams.edu

44

45 Joshua L. Kennedy

46 Mailing address: 13 Children's Way, Slot 512-13, Little Rock, AR 72205

47 Phone: (501) 364-1060

48 Email: jlkenedy@uams.edu

49

50 **Funding:** We acknowledge funding from the state of Arkansas through the Coronavirus Aid,
51 Relief, and Economic Security (CARES) Act, the UAMS Time-Sensitive COVID-10 Research
52 Award Program, the UAMS Translational Research Institute (UL1TR000039, TL1TR003109,
53 and UL1TR003107), and the Center for Microbial Pathogenesis and Host Inflammatory
54 Response (P20 GM103625). The funders had no role in the study design, data collection, and
55 interpretation.

56

57 **Conflicts of interest:** None

58 **ABSTRACT (Word count: 200)**

59 **Background:** SARS-CoV-2 seroprevalence studies have largely focused on adults but little is
60 known about spread in children. We determined SARS-CoV-2 seroprevalence in children and
61 adolescents from Arkansas over the first year of the COVID-19 pandemic. **Methods:** We tested
62 remnant serum samples from children from 1–18 years who visited Arkansas hospitals or clinics
63 for non-COVID19-related reasons from April, 2020 through April, 2021 for SARS-CoV-2
64 antibodies. We used univariable and multivariable regression models to determine association
65 between seropositivity and participant characteristics. **Results:** Among 2400 participants,
66 seroprevalence rose from 7.9% in April/May 2020 (95% CI, 4.9-10.9%) to 25.8% in April 2021
67 (95% CI, 22.2-29.3%). Hispanic and black children had a significantly higher association with
68 antibody positivity than white children in multiple sampling periods. **Conclusions:** By spring
69 2021, most children in Arkansas had not been infected with SARS-CoV-2. With the emergence
70 of SARS-CoV-2 variants, recognition of long-term effects of COVID-19, and the lack of an
71 authorized pediatric SARS-CoV-2 vaccine, these results highlight the importance of including
72 children in SARS-CoV-2 public health, clinical care, and research strategies. These findings are
73 important for state and local officials as they consider measures to limit SARS-CoV-2 spread in
74 schools and daycares for the 2021–2022 school year.

75

76

77 **Keywords:** COVID-19, SARS-CoV2, serology, serum, antibody, child, epidemiology

78 **TEXT (Word count: 3,152)**

79 **INTRODUCTION**

80 Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) emerged in late 2019
81 and spread globally to cause the coronavirus disease of 2019 (COVID-19) pandemic [1, 2].
82 SARS-CoV-2 has infected nearly 200 million and killed more than 4 million people worldwide,
83 causing massive disruptions to daily life and untold economic losses [3]. SARS-CoV-2 was first
84 detected in the United States in early 2020 and has caused over 600,000 deaths [4-6] Children
85 were thought to be important for driving SARS-CoV-2 transmission [7, 8]. In March 2020,
86 schools nationwide closed for in-person instruction and classes moved online to curtail SARS-
87 CoV-2 spread [7, 8]. However, pediatric infection rates, and thereby the potential level of
88 immunity in children, is not known [9, 10]. Because approval of SARS-CoV-2 vaccines for those
89 12 years and under is not expected until late 2021, knowing infection rates in children is
90 important information for school officials as they consider risks and protection measures for the
91 2021–2022 school year.

92 Children typically experience less severe COVID-19 and may be more likely to have
93 asymptomatic infections, allowing them to unknowingly spread SARS-CoV-2 [11]. With
94 asymptomatic infections estimated as high as 50%, estimating true infection rates remains
95 challenging [12, 13]. Although nucleic acid testing can identify active SARS-CoV-2 cases, most
96 infections clear within two weeks and leave asymptomatic cases undocumented [12-14].
97 Antibodies generated against prior infections can last for months to years [10, 15]. The
98 presence of SARS-CoV-2 antibodies in the blood can indicate that a person was infected at
99 some point in the pandemic. Serological studies can capture asymptomatic and symptomatic
100 cases, and more accurately estimate of how many people have been infected with SARS-CoV-2
101 [10, 15]. Here, we present the results of a seroprevalence study of children ages 1–18 years of
102 age who visited hospitals or regional clinics in Arkansas for non-COVID19-related reasons over
103 the first year of the COVID-19 pandemic.

104 **METHODS**

105 **Human specimens.** All human specimens were obtained with oversight from the UAMS
106 Institutional Review Board (IRB), and waiver of consent and HIPAA applied. Remnants of serum
107 samples collected for routine, non-COVID-19-related clinical laboratory tests were obtained from
108 Arkansas Children's Hospital (ACH, Little Rock, AR), Arkansas Children's Northwest
109 (Springdale, AR), and UAMS Family Medical Centers (Ft. Smith, AR and Pine Bluff, AR).
110 Samples were de-identified prior to testing. Inclusion criteria were ages 1–18 years and
111 Arkansas resident. Samples were excluded with the following diagnosis codes:
112 immunodeficiency (primary immune deficiency (D80–D89)), transplant recipient (codes
113 beginning with Z94), and cancer (C00–D49). Samples from patients receiving chemotherapy
114 (prior two months), steroids (prior 30 days), and/or intravenous immunoglobulin (prior 6 months)
115 were excluded. Samples were selected by pathologists at each clinic after they were considered
116 remnant. Clinical and demographic variables were stored in a secure REDCap database [16,
117 17] and included age, sex, race/ethnicity, zip code, and county of residence. Metropolitan status
118 was determined by cross-1.0 (Ref)erencing zip codes with the Federal Office of Rural Health
119 Policy (FORHP) data files identifying non-metropolitan counties and rural census tracts.

120 **Protein production and purification.** HEK293T cells were cultured in Dulbecco's
121 minimum essential media (DMEM; Gibco) supplemented with 10% heat-inactivated calf serum
122 (CS, VWR), 2 mM L-glutamine (Invitrogen), and 100 U/mL penicillin/100 µg/mL streptomycin
123 (Invitrogen). Briefly, 15 cm dishes seeded with 9×10^6 cells on the preceding day were
124 transfected with 20 µg of pCAGGS-SARS-CoV-2 Wuhan-Hu-1 RBD-C-terminal 6-His tag (BEI
125 Resources), pCAGGS SARS-CoV-2 Wuhan-Hu-1 ectodomain Spike glycoprotein gene-C-
126 terminal 6-His tag, or pCMV3 2019-nCoV nucleoprotein-C-terminal 6-His tag (Sino Biological)
127 using polyethylamine (PEI) at a 1:3 ratio. DNA:PEI mixtures were incubated at RT for 10 mins
128 and added to cells with the media volume reduced to 5 mL/dish. After 4–6 hours, the media
129 volume was raised to 25 mL. SARS-CoV-2 RBD and Spike ectodomain proteins were purified

130 as described [18]. Nucleoprotein (N) was isolated as described above under denaturing
131 conditions [19]. Protein concentration was measured by DC Protein Assay (BioRad). Purified
132 proteins were confirmed by Coomassie and western blot using antigen-specific antibodies and
133 stored at -80°C .

134 **ELISAs.** Serum was inactivated at 56°C for 1 h and initially screened by ELISA specific
135 for the receptor-binding domain (RBD) of the SARS-CoV-2 S protein [20-26]. Commercial anti-
136 RBD (Sino Biologicals; 1:2500 dilution) and SARS-CoV-2-RT-PCR-positive patient sera (1:50
137 dilution) served as positive controls. Purified human IgG (Sigma; 1:2500 dilution) and pre-
138 COVID-19 patient sera (1:50 dilution) served as negative controls. Serum IgM and IgG were
139 detected using horse-radish peroxidase-conjugated anti-human IgM+IgG (Jackson
140 ImmunoResearch; diluted 1:5000 in PBS-T + 1% milk) and SureBlue TMB 1-Component
141 Peroxidase Substrate (SeraCare; 75 μL). After 5 min, the reaction was terminated using TMB
142 Stop Solution (SeraCare; 75 μL). The OD_{450} was measured using a FluoStar Omega plate
143 reader (BMG Labtech). The final OD_{450} was calculated by subtracting the mean OD_{450} of blank
144 wells from the mean OD_{450} of duplicate samples. The statistical cutoff for RBD binding was
145 defined as the mean OD_{450} + 3 standard deviations of pre-COVID-19 sera [26].

146 Confirmation RBD-positive specimens was performed using a Four-Antigen Confirmation
147 Test (FACT) ELISA. An additional 5% of negative sera were randomly selected and tested in
148 parallel. Plates were coated with 2 $\mu\text{g}/\text{mL}$ RBD, spike, nucleoprotein, or bovine serum albumin
149 (BSA; Sigma Aldrich) and FACT ELISA was performed as above. Confirmed positive samples
150 were defined by (i) a mean signal for any viral antigen over 0.6 OD_{450} , (ii) BSA-subtracted viral
151 antigen value $>0.3 \text{OD}_{450}$, (iii) and at least two positive antigens (RBD+/Spike+, RBD+/N+,
152 Spike+/N+, or RBD+/Spike+/N+). The sensitivity and specificity of the assay were 94.6% and
153 100%, respectively, based on 37 pre-COVID-19 and 19 RT-PCR-confirmed SARS-CoV-2-
154 positive sera.

155 **Statistical analyses.** The descriptive analysis was conducted for the study population
156 demographics by wave. SARS-CoV-2 antibody positivity rates were reported with 95%
157 confidence intervals (CI) using exact binomial distributions. The 2019 U.S. Census Bureau
158 Arkansas state population estimates (age \leq 18) were used to calculate the standardized
159 positivity rates [27]. The age- and sex-standardized positivity rates were reported for each wave.
160 Univariable and multivariable analyses were performed to examine the relationship between
161 variables and the SARS-CoV-2 antibody positivity rate for each wave. Relative risk was
162 estimated by modified Poisson regressions with robust error variance as the measure to
163 characterize association effects [28]. For multivariable analyses, factors being considered were
164 age group, sex, and race/ethnicity. The statistical significance level was set at 0.05. We
165 conducted all analyses using SAS version 9.4 (SAS Institute).

166

167 **RESULTS**

168 **Enrollment and demographic representation.** We collected 2400 total remnant
169 pediatric serum samples across five collection periods (waves): Wave 1, April 2 – May 6, 2020
170 (n = 316); Wave 2, June 6 – August 10, 2020, (n = 300); Wave 3, September 8 – October 17,
171 2020, (n = 594); Wave 4, November 7 – December 17, 2020, (n = 600); and Wave 5, April 5 –
172 April 28, 2021, (n = 590) (Figure 1). Table 1 shows the demographic characteristics for the
173 study. The 1 – 4 years age group had the fewest samples (n = 328, 13.7%) while the 10 – 14
174 years group had the most samples (n = 795, 33.2%). Females represented 54.8% (n = 1311),
175 whereas males represented 45.2% (n = 1082) of total samples analyzed. The racial/ethnic
176 distribution of the study population was 55.8% non-Hispanic white (n = 1289), 22.5% non-
177 Hispanic black (n = 520), and 15.2% Hispanic (n = 351). A total of 151 specimens (6.5%) were
178 collected from patients that did not identify as white, black, or Hispanic. Most samples were
179 collected from children living in urban (n = 1564, 75.3%) compared to rural areas (n = 513,
180 24.7%). Obesity was the most common co-morbidity reported (n = 337, 14.1%), followed by

181 asthma (n = 239, 10.0%), diabetes mellitus (n = 113, 4.7%), and hypertension (n = 111, 4.6%)
182 (Supplemental table 1).

183 **Estimates of seroprevalence.** Table 2 shows the SARS-CoV-2 seroprevalence rates
184 by age, sex, and race/ethnicity, and the age- and sex-standardized estimates. The antibody
185 positivity rate for Wave 1 was 7.9% (95% CI, 4.9%-10.9%), which increased in Wave 2 to 9.7%
186 (95% CI, 6.3%-13.0%) and Wave 3 to 16.2% (95% CI, 13.2%-19.1%), followed by a slight
187 decrease to 13.2% (95% CI, 10.5%-15.9%) in Wave 4. The seroprevalence rate was the highest
188 in Wave 5 at 25.8% (95% CI, 22.2%-29.3%). The overall trend was statistically significant
189 ($p < 0.0001$ using the Cochran-Armitage trend test). When standardized to match Arkansas
190 population demographics [27], seroprevalence rates followed a similar trend to the non-adjusted
191 rates, increasing over Waves 1, 2, and 3, with a decrease in Wave 4 and a peak of 24.2% (95%
192 CI, 22.2%-29.3%) in Wave 5 (Figure 2). The 1 – 4 year-old age group had the highest
193 seroprevalence rates in Wave 1 (10.7%), Wave 2 (15.2%), and Wave 3 (19.8%), but the lowest
194 in Wave 4 (7.2%) and Wave 5 (16.0%). The 15 – 18 year-old group had the highest percentage
195 of reactive specimens in Wave 4 (14.8%) and 10 – 14 year-olds were the highest in Wave 5
196 (30.9%). No statistically-significant difference was observed between males and females.

197 Hispanics had the highest seroprevalence rate in each wave, reaching a maximum of
198 43.7% in Wave 5. White persons had a higher seroprevalence rate in Waves 1 and 2, but the
199 lowest in Waves 3, 4, and 5. Concomitantly, the antibody reactivity rate in black persons was
200 lower compared to white persons in Waves 1 and 2, but higher in Waves 3, 4, and 5. The
201 highest seroprevalence rates for white (17.9%) and black (28.2%) children was observed in
202 Wave 5. Notably, the peak seroprevalence for Hispanic children was 5.5-fold higher compared
203 to white children and 1.6-fold higher than black children.

204 There was no significant marginal association between age, sex, or metropolitan status
205 and the likelihood of testing positive for SARS-CoV-2 antibodies (Supplemental table 2).
206 However, Hispanic and black children were more likely to test positive for antibodies than white

207 children during multiple waves after adjusting for age and sex. Hispanic children showed a
208 higher relative risk of testing positive compared to white children in Wave 3 (RR 2.82 95% CI,
209 1.81-4.38), Wave 4 (RR 1.76 95% CI, 1.03-3.00), and Wave 5 (RR 2.37 95% CI 1.69-3.33).
210 Blacks also showed a higher risk of having antibodies compared to white children in Wave 3
211 (RR 1.71 95% CI, 1.03-2.84) and Wave 5 (RR 1.59 95% CI, 1.08-2.34). The risk of testing
212 positive for antibodies was higher for children of other races/ethnicities in Wave 3 (RR 2.59 95%
213 CI, 1.36-4.92) and Wave 5 (RR 2.14 95% CI, 1.35-3.40).

214 Children with asthma (unadjusted RR 4.83 95% CI, 1.96-11.87; $P = 0.003$) or diabetes
215 (unadjusted RR 4.17 95% CI, 1.49-11.67; $P = 0.007$) had higher risk of having antibodies of
216 SARS-CoV-2 than children who did not have asthma or diabetes in Wave 1 (Supplemental table
217 3). However, this difference was not observed in the remaining waves. PCR testing was
218 performed for 714 of 2400 total specimens, with 38 positive PCR tests reported (Supplemental
219 table 4). A positive RT-PCR test was significantly associated with antibody positivity in Waves 2
220 through 5 (Supplemental table 5).

221

222 **DISCUSSION**

223 Our results demonstrate that by the end of April 2021, approximately 25% of children in
224 Arkansas had SARS-CoV-2-specific antibodies. This percentage is much higher than the total
225 number of confirmed cases, which on April 28, 2021 was 11% for the total population of
226 Arkansas (335,288 positive cases according the Arkansas Department of Health, population of
227 3,011,524 according to 2019 census data). This finding indicates that those children had been
228 infected with SARS-CoV-2 and are likely to have at least some natural immunity. Conversely,
229 our findings suggest that most children in Arkansas have not been infected with SARS-CoV-2
230 and remain susceptible to infection. Although COVID-19 has been less severe in children than
231 adults early in the pandemic, emergence of the SARS-CoV-2 delta variant in May 2021 has
232 driven up infection and hospitalization rates, including among those under 18 years of age [11,

233 29, 30]. Developing multisystem inflammatory syndrome in children (MIS-C), a severe
234 inflammatory disorder that results from a current or recent SARS-CoV-2 infection, is also a risk
235 for those under 18 years [31-33]. Increased SARS-CoV-2 transmission rates combined with a
236 highly susceptible pediatric population raises the possibility that SARS-CoV-2 could spread
237 rapidly in schools and daycares during the upcoming school year. More children infected with
238 SARS-CoV-2 could lead to an increase in the number of severe COVID-19 and MIS-C cases,
239 and a rise in pediatric deaths.

240 The first SARS-CoV-2 infections in Arkansas were reported in March 2020 (Figure 1)
241 [34]. Arkansas schools suspended in-person learning on March 15, 2020 and many activities
242 where children congregate during the summer were closed. We found that the seroprevalence
243 rate in children increased modestly between spring and summer, suggesting that these
244 protective measures effectively limited SARS-CoV-2 spread among children in Arkansas. The
245 larger increase in seroprevalence for September/October (Wave 3), corresponded with the start
246 of the 2020 – 2021 school year. However, masks and social distancing measures were in place,
247 and many Arkansas students began the school year as remote learners. These actions likely
248 reduced SARS-CoV-2 spread in schools, as reported outbreaks were relatively rare. Despite a
249 dramatic increase in SARS-CoV-2 cases in Arkansas during November and December, the
250 seroprevalence rate in children dropped during Wave 4 [35]. The decrease suggests that
251 preventative measures in schools were effective at limiting SARS-CoV-2 spread among children
252 during this time. However, seroprevalence increased sharply in Wave 5 to approximately 25%.
253 Waves 4 and 5 were approximately three months apart and included the winter holidays, when
254 children were outside the controlled school setting, and the corresponding nationwide surge in
255 COVID-19 cases. Our data confirm that the surge also impacted the pediatric population,
256 correlating with a large increase in the number of SARS-CoV-2-exposed children.

257 It is well appreciated that underrepresented racial and ethnic groups are
258 disproportionately affected by the COVID-19 pandemic [36]. We found that Hispanic children

259 were more likely to have SARS-CoV-2 antibodies compared to white children in all waves.
260 Similarly, black children were more likely to have antibodies than white children in Wave 3 and
261 Wave 5. The increase in SARS-CoV-2 antibodies in Hispanic and black children corresponded
262 to an increase in antibody level in Hispanic and black adults during the same timeframe.(REF-
263 Kennedy preprint) Higher antibody prevalence in Hispanic and black children may reflect
264 multiple socioeconomic factors, including income inequality, economic stability, work
265 circumstances, and housing [37]. Hispanic and black parents may be less likely to hold jobs that
266 allow them to work remotely, which increases their potential exposure to SARS-CoV-2 in the
267 workplace and limits their ability to utilize remote learning or in home childcare to decrease their
268 children's SARS-CoV-2 exposure [38, 39]. Residing with parents with a higher risk of workplace
269 SARS-CoV-2 exposure combined with increased school/daycare attendance could drive
270 infection rates in minority children. Our results underscore that the pandemic exacerbated
271 existing racial and ethnic disparities.

272 Our data also highlight the importance of vaccinating children against SARS-CoV-2.
273 General vaccinations in Arkansas began in January 2021 for those over 18 years and, and were
274 expanded to 16 years and older on March 30, 2021 [40]. The CDC's Advisory Committee on
275 Immunization Practices recommended the Pfizer-BioNTech vaccine for 12-15 year-olds on May
276 10, 2021 [40]. Wave 5 samples were collected in April 2021, after the expansion of vaccinations
277 to those 16 years and up but prior to inclusion of 12 – 15 year-olds. Only 8 of 145 total 16 – 18
278 year-olds in reported being vaccinated during Wave 5 and no subjects reported full vaccination
279 at least two weeks prior to sample collection. Thus, our data reflect the pediatric seroprevalence
280 rate in Arkansas prior to widespread vaccination efforts in children and adolescents. As
281 authorization to vaccinate children younger than 12 years will not occur until late 2021, our
282 findings indicate that most children in Arkansas remain susceptible to SARS-CoV-2 infection
283 entering the 2021 – 2022 school year. Importantly, we found that the seroprevalence rate in
284 younger children was lower than for older children and adolescents, which strongly emphasizes

285 the ongoing risk of infection for a vulnerable part of the population that cannot yet be
286 vaccinated. This is a critical consideration for policy makers as more infectious variants emerge
287 that exhibit increased infection and likelihood of causing severe disease in younger portions of
288 the population.

289 **Limitations**

290 Remnant serum samples may not provide an accurate representation of the Arkansas
291 population. The strengths and limitations of convenience samples are described elsewhere [41].
292 As our study samples were collected from health clinics, our sampling method may favor
293 subjects who were more ill or more willing to seek health care. It is possible that our
294 seroprevalence rates are overestimated due to potential cross reactivity between SARS-CoV-2
295 antigens and seasonal coronaviruses [42]. Some uninfected individuals, particularly children
296 and adolescents, have antibodies that react with the SARS-CoV-2 Spike protein [42]. Further,
297 we measured a combination of IgM and IgG antibody isotypes, as opposed to testing solely for
298 IgG [43]. Although studies indicate that IgG and IgM responses to SARS-CoV-2 can develop
299 simultaneously, some individuals develop detectable IgM and IgG antibodies at different times
300 [44, 45]. Consequently, we may identify individuals with IgM and/or IgG, whereas other assays
301 may only identify specimens with IgG. IgM also can be more non-specific than IgG [46].
302 Together, these limitations may cause an overestimation of antibody reactivity. However,
303 inclusion of multiple SARS-CoV-2 antigens and the BSA control limit the non-specific reactions
304 detected in our assay.

305

306 **CONCLUSIONS**

307 Analysis of remnant samples collected from children and adolescents in Arkansas
308 demonstrate a steady increase in SARS-CoV-2 infection during the first 8 months of the
309 pandemic, followed by a more rapid increase to 25% by the end of April 2021. This finding is
310 notable, as it is more than twice the number of confirmed SARS-CoV-2 diagnoses in the state

311 on the final collection date. No obvious comorbidities were identified for seropositivity in
312 children. Racial and ethnic disparities exist, with Hispanic and black children being at increased
313 risk for SARS-CoV-2 infection compared to white children. We conclude that SARS-CoV-2
314 infections in children are more common than previously recognized. With the emergence of
315 SARS-CoV-2 variants, recognition of long-term effects of SARS-CoV-2 even after mild or
316 asymptomatic infections, and the lack of an authorized pediatric SARS-CoV-2 vaccine, these
317 results highlight the importance of including children in SARS-CoV-2 public health, clinical care,
318 and research strategies. Until vaccines are approved for those under 12 years, it is important
319 that protective measures are enacted, particularly in settings where children are grouped
320 together, to limit the risk of infection, super-spreader events, severe disease, long-term
321 sequelae, and death. This is especially true in states like Arkansas with low vaccination rates,
322 which is currently experiencing a new surge in infections and hospitalizations in younger age-
323 groups caused by more infectious SARS-CoV-2 variants.

324

325 **ACKNOWLEDGMENTS**

326 This research was supported by funds from the state of Arkansas through the
327 Coronavirus Aid, Relief, and Economic Security (CARES) Act, the UAMS Time-Sensitive
328 COVID-10 Research Award Program, the UAMS Translational Research Institute
329 (UL1TR000039, TL1TR003109, and UL1TR003107), and the Center for Microbial Pathogenesis
330 and Host Inflammatory Response (National Institutes of Health, National Institute for General
331 Medical Sciences P20 GM103625).

332 **FIGURE LEGENDS**

333 **Figure 1** Timeline of Arkansas COVID-19 milestones and sample collection waves. The
334 schematic shows the timeline for relevant study-related events. The sample collection periods
335 (waves) are indicated by blue boxes. The age- and sex-standardized seroprevalence rate for
336 each wave is indicated as the percent (95% CI).

337

338 **Figure 2** Age- and sex-standardized seroprevalence rates by wave. Error bars indicate 95% CI.

339 **REFERENCES**

- 340 1. Lu H, Stratton CW, Tang YW. Outbreak of pneumonia of unknown etiology in Wuhan, China:
341 The mystery and the miracle. *J Med Virol* **2020**; 92:401-2.
- 342 2. Zhu N, Zhang D, Wang W, et al. A Novel Coronavirus from Patients with Pneumonia in
343 China, 2019. *N Engl J Med* **2020**; 382:727-33.
- 344 3. World Health Organization. Available at: <https://covid19.who.int/>.
- 345 4. Team CC-R, Jordan MA, Rudman SL, et al. Evidence for Limited Early Spread of COVID-19
346 Within the United States, January-February 2020. *MMWR Morb Mortal Wkly Rep* **2020**; 69:680-
347 4.
- 348 5. United States Centers for Disease Control and Prevention. Available at:
349 <https://covid.cdc.gov/covid-data-tracker/#datatracker-home>.
- 350 6. Holshue ML, DeBolt C, Lindquist S, et al. First Case of 2019 Novel Coronavirus in the United
351 States. *N Engl J Med* **2020**; 382:929-36.
- 352 7. Jean-Baptiste CO, Herring RP, Beeson WL, Dos Santos H, Banta JE. Stressful life events
353 and social capital during the early phase of COVID-19 in the U.S. *Soc Sci Humanit Open* **2020**;
354 2:100057.
- 355 8. Bayham J, Fenichel EP. Impact of school closures for COVID-19 on the US health-care
356 workforce and net mortality: a modelling study. *Lancet Public Health* **2020**; 5:e271-e8.
- 357 9. Hobbs CV, Drobeniuc J, Kittle T, et al. Estimated SARS-CoV-2 Seroprevalence Among
358 Persons Aged <18 Years - Mississippi, May-September 2020. *MMWR Morb Mortal Wkly Rep*
359 **2021**; 70:312-5.
- 360 10. Bajema KL, Wiegand RE, Cuffe K, et al. Estimated SARS-CoV-2 Seroprevalence in the US
361 as of September 2020. *JAMA Intern Med* **2021**; 181:450-60.
- 362 11. Dong Y, Mo X, Hu Y, et al. Epidemiology of COVID-19 Among Children in China. *Pediatrics*
363 **2020**; 145.

- 364 12. Oran DP, Topol EJ. Prevalence of Asymptomatic SARS-CoV-2 Infection. *Ann Intern Med*
365 **2021**; 174:286-7.
- 366 13. Oran DP, Topol EJ. The Proportion of SARS-CoV-2 Infections That Are Asymptomatic : A
367 Systematic Review. *Ann Intern Med* **2021**; 174:655-62.
- 368 14. United States Centers for Disease Control and Prevention. Available at:
369 <https://www.cdc.gov/coronavirus/2019-ncov/lab/testing.html>.
- 370 15. Havers FP, Reed C, Lim T, et al. Seroprevalence of Antibodies to SARS-CoV-2 in 10 Sites
371 in the United States, March 23-May 12, 2020. *JAMA Intern Med* **2020**.
- 372 16. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data
373 capture (REDCap)--a metadata-driven methodology and workflow process for providing
374 translational research informatics support. *J Biomed Inform* **2009**; 42:377-81.
- 375 17. Harris PA, Taylor R, Minor BL, et al. The REDCap consortium: Building an international
376 community of software platform partners. *J Biomed Inform* **2019**; 95:103208.
- 377 18. Stadlbauer D, Amanat F, Chromikova V, et al. SARS-CoV-2 Seroconversion in Humans: A
378 Detailed Protocol for a Serological Assay, Antigen Production, and Test Setup. *Curr Protoc*
379 *Microbiol* **2020**; 57:e100.
- 380 19. Mark J, Li X, Cyr T, Fournier S, Jaentschke B, Hefford MA. SARS coronavirus: unusual
381 lability of the nucleocapsid protein. *Biochem Biophys Res Commun* **2008**; 377:429-33.
- 382 20. Leclercq I, Batejat C, Burguiere AM, Manuguerra JC. Heat inactivation of the Middle East
383 respiratory syndrome coronavirus. *Influenza Other Respir Viruses* **2014**; 8:585-6.
- 384 21. Yunoki M, Urayama T, Yamamoto I, Abe S, Ikuta K. Heat sensitivity of a SARS-associated
385 coronavirus introduced into plasma products. *Vox Sang* **2004**; 87:302-3.
- 386 22. Rabenau HF, Cinatl J, Morgenstern B, Bauer G, Preiser W, Doerr HW. Stability and
387 inactivation of SARS coronavirus. *Med Microbiol Immunol* **2005**; 194:1-6.
- 388 23. Kariwa H, Fujii N, Takashima I. Inactivation of SARS coronavirus by means of povidone-
389 iodine, physical conditions and chemical reagents. *Dermatology* **2006**; 212 Suppl 1:119-23.

- 390 24. Duan SM, Zhao XS, Wen RF, et al. Stability of SARS coronavirus in human specimens and
391 environment and its sensitivity to heating and UV irradiation. *Biomed Environ Sci* **2003**; 16:246-
392 55.
- 393 25. Chang L, Yan Y, Wang L. Coronavirus Disease 2019: Coronaviruses and Blood Safety.
394 *Transfus Med Rev* **2020**; 34:75-80.
- 395 26. Amanat F, Stadlbauer D, Strohmeier S, et al. A serological assay to detect SARS-CoV-2
396 seroconversion in humans. *Nat Med* **2020**; 26:1033-6.
- 397 27. United States Census Bureau. Available at: <https://www.census.gov/quickfacts/AR>.
398 Accessed May 14 2021.
- 399 28. Zou G. A modified poisson regression approach to prospective studies with binary data. *Am*
400 *J Epidemiol* **2004**; 159:702-6.
- 401 29. Havers FP, Whitaker M, Self JL, et al. Hospitalization of Adolescents Aged 12-17 Years with
402 Laboratory-Confirmed COVID-19 - COVID-NET, 14 States, March 1, 2020-April 24, 2021.
403 *MMWR Morb Mortal Wkly Rep* **2021**; 70:851-7.
- 404 30. Dougherty K, Mannell M, Naqvi O, Matson D, Stone J. SARS-CoV-2 B.1.617.2 (Delta)
405 Variant COVID-19 Outbreak Associated with a Gymnastics Facility - Oklahoma, April-May 2021.
406 *MMWR Morb Mortal Wkly Rep* **2021**; 70:1004-7.
- 407 31. Dufort EM, Koumans EH, Chow EJ, et al. Multisystem Inflammatory Syndrome in Children in
408 New York State. *N Engl J Med* **2020**; 383:347-58.
- 409 32. Feldstein LR, Rose EB, Horwitz SM, et al. Multisystem Inflammatory Syndrome in U.S.
410 Children and Adolescents. *N Engl J Med* **2020**; 383:334-46.
- 411 33. Ouldali N, Yang DD, Madhi F, et al. Factors Associated With Severe SARS-CoV-2 Infection.
412 *Pediatrics* **2021**; 147.
- 413 34. James A, Eagle L, Phillips C, et al. High COVID-19 Attack Rate Among Attendees at Events
414 at a Church - Arkansas, March 2020. *MMWR Morb Mortal Wkly Rep* **2020**; 69:632-5.

- 415 35. Arkansas Department of Health. Available at:
416 <https://experience.arcgis.com/experience/633006d0782b4544bd5113a314f6268a/>. Accessed
417 July 20 2021.
- 418 36. Khunti K, Platt L, Routen A, Abbasi K. Covid-19 and ethnic minorities: an urgent agenda for
419 overdue action. *BMJ* **2020**; 369:m2503.
- 420 37. United States Bureau of Labor Statistics. Available at:
421 <https://www.bls.gov/opub/reports/race-and-ethnicity/2019/home.htm>. Accessed July 22 2021.
- 422 38. Yancy CW. COVID-19 and African Americans. *JAMA* **2020**; 323:1891-2.
- 423 39. Ambrose AJH. Inequities During COVID-19. *Pediatrics* **2020**; 146.
- 424 40. Arkansas Pharmacists Association. Available at: <https://www.arrx.org/covid-vaccine>.
425 Accessed May 30 2021.
- 426 41. Shook-Sa BE, Boyce RM, Aiello AE. Estimation Without Representation: Early Severe Acute
427 Respiratory Syndrome Coronavirus 2 Seroprevalence Studies and the Path Forward. *J Infect*
428 *Dis* **2020**; 222:1086-9.
- 429 42. Ng KW, Faulkner N, Cornish GH, et al. Preexisting and de novo humoral immunity to SARS-
430 CoV-2 in humans. *Science* **2020**; 370:1339-43.
- 431 43. Oved K, Olmer L, Shemer-Avni Y, et al. Multi-center nationwide comparison of seven
432 serology assays reveals a SARS-CoV-2 non-responding seronegative subpopulation.
433 *EClinicalMedicine* **2020**; 29:100651.
- 434 44. Long QX, Liu BZ, Deng HJ, et al. Antibody responses to SARS-CoV-2 in patients with
435 COVID-19. *Nat Med* **2020**; 26:845-8.
- 436 45. Long QX, Tang XJ, Shi QL, et al. Clinical and immunological assessment of asymptomatic
437 SARS-CoV-2 infections. *Nat Med* **2020**; 26:1200-4.
- 438 46. Shah J, Liu S, Potula HH, et al. IgG and IgM antibody formation to spike and nucleocapsid
439 proteins in COVID-19 characterized by multiplex immunoblot assays. *BMC Infect Dis* **2021**;
440 21:325.

Table 1. Sample population demographics for SARS-CoV-2 antibody testing in Arkansas from April 2, 2020 to April 28, 2021.

Number (%) ^a						
Characteristic	Wave 1 (n = 316)	Wave 2 (n = 300)	Wave 3 (n = 594)	Wave 4 (n = 600)	Wave 5 (n = 590)	Overall (N = 2400)
Collection dates	April 2 – May 6, 2020	June 6 – August 10, 2020	September 8 – October 17, 2020	November 7 – December 17, 2020	April 5 – April 28, 2021	April 2, 2020 – April 28, 2021
Age category						
1-4 years	56 (17.7)	33 (11)	81 (13.6)	83 (13.9)	75 (12.8)	328 (13.7)
5-9 years	61 (19.3)	75 (25)	112 (18.9)	116 (19.5)	142 (24.2)	506 (21.1)
10-14 years	90 (28.5)	98 (32.7)	205 (34.5)	214 (36.0)	188 (32)	795 (33.2)
15-18 years	109 (34.5)	94 (31.3)	196 (33)	182 (30.6)	183 (31.1)	764 (31.9)
Sex						
Female	161 (50.9)	155 (51.7)	324 (54.5)	338 (56.8)	333 (56.5)	1311 (54.8)
Male	155 (49.1)	145 (48.3)	270 (45.5)	257 (43.2)	255 (43.2)	1082 (45.2)
Race/Ethnicity						
White	178 (56.5)	154 (52.2)	327 (57.2)	312 (54.5)	318 (57.2)	1289 (55.8)
Black	91 (28.9)	53 (18.0)	117 (20.5)	150 (26.2)	109 (19.6)	520 (22.5)
Hispanic	28 (8.9)	64 (21.7)	95 (16.6)	77 (13.4)	87 (15.7)	351 (15.2)
Other	18 (5.7)	24 (8.1)	33 (5.8)	34 (5.9)	42 (7.6)	151 (6.5)
Metropolitan status ^b						
Urban	Not Reported	251 (83.7)	458 (77.1)	424 (71.3)	431 (73.3)	1564 (75.3)
Rural	Not Reported	49 (16.3)	136 (22.9)	171 (28.7)	157 (26.7)	513 (24.7)

443

444

445

446

^aPercentages calculated from non-missing values for all periods. Missing values in Wave 1 included race/ethnicity (n = 1) and metropolitan status (n = 316). Missing values in Wave 2 included race/ethnicity (n = 5). Missing values in Wave 3 included race/ethnicity (n = 22). Missing values in Wave 4 included age category (n = 5), sex (n = 5), race/ethnicity (n = 27), and metropolitan status (n = 5). Missing values in Wave 5 included age category (n = 4), sex (n = 2), race/ethnicity (n = 34), and metropolitan status (n = 2).

447 **Table 2. Age-specific, sex-specific, race/ethnicity-specific SARS-CoV-2 seroprevalence estimates in Arkansas from April 2, 2020 to**
 448 **April 28, 2021.**

Persons reactive, % (95% CI) (No.)					
Characteristic	Wave 1 (n = 316)	Wave 2 (n = 300)	Wave 3 (n = 594)	Wave 4 (n = 600)	Wave 5 (n = 590)
Collection dates	April 2 – May 6, 2020	June 6 – August 10, 2020	September 8 – October 17, 2020	November 7 – December 17, 2020	April 5 – April 28, 2021
Age category					
1-4 years	10.7 (2.4-19.1) (6)	15.2 (2.2-28.1) (5)	19.8 (10.9-28.6) (16)	7.2 (1.54-12.9) (6)	16.0 (7.5-24.5) (12)
5-9 years	4.9 (0.0-10.5) (3)	8.0 (1.7, 14.3) (6)	18.8 (11.4-26.1) (21)	12.9 (6.7-19.1) (15)	19.0 (12.5,-25.5) (27)
10-14 years	8.9 (2.9-14.9) (8)	11.2 (4.9-17.6) (11)	14.2 (9.3-19.0) (29)	14.0 (9.3-18.7) (30)	30.9 (24.2-37.5) (58)
15-18 years	7.3 (1.4-12.3) (8)	7.4 (2.0-12.9) (7)	15.3 (10.2-20.4) (30)	14.8 (9.6-20.0) (27)	29.5 (22.8-36.2) (54)
Sex					
Female	8.7 (4.3-13.1) (14)	9.0 (4.5-13.6) (14)	17.3 (13.1-21.4) (56)	13.6 (9.9-17.3) (46)	27.0 (22.2-31.8) (90)
Male	7.1 (3.0-11.2) (11)	10.3 (5.3-15.4) (15)	14.8 (10.6-19.1) (40)	12.5 (8.4-16.5) (32)	23.9 (18.7-29.2) (61)
Race/Ethnicity					
White	9.0 (4.7-13.2) (16)	9.7 (5.0-14.5) (15)	10.7 (7.3-14.1) (35)	11.5 (8.0-15.1) (36)	17.9 (13.7-22.2) (57)
Black	5.5 (0.7-10.3) (5)	3.8 (0.0-9.1) (2)	17.1 (10.2-24.0) (20)	15.3 (9.5-21.2) (23)	28.4 (19.8-37.0) (31)
Hispanic	10.7 (0.0-22.9) (3)	14.1 (5.3-22.8) (9)	29.5 (20.1-38.8) (28)	20.8 (11.5-30.0) (16)	43.7 (33.0-54.3) (38)
Other	5.6 (0.0 -7.3) (1)	12.5 (0.0-26.8) (3)	27.3 (11.2-43.4) (9)	2.9 (0.0-8.9) (1)	35.7 (20.6-50.8) (15)
Total	7.9 (4.9-10.9) (25)	9.7 (6.3-13.0) (29)	16.2 (13.2-19.1) (96)	13.2 (10.5-15.9) (79)	25.8 (22.2-29.3) (152)

449

450

^aStandardized positivity rates were calculated based on the 2019 U.S. Census Bureau Arkansas state population estimates (age ≤ 18).²⁷

451 **Table 3. Age- and sex-adjusted association with SARS-CoV-2 antibody positivity by time period.**

Adjusted RR (95% CI)					
Characteristic	Wave 1 (n = 316)	Wave 2 (n = 300)	Wave 3 (n = 594)	Wave 4 (n = 600)	Wave 5 (n = 592)
Collection dates	April 2 – May 6, 2020	June 6 – August 10, 2020	September 8 – October 17, 2020	November 7 – December 17, 2020	April 5 – April 28, 2021
Age category					
1-4 years	1.66 (0.55-5.02)	1.89 (0.67-5.35)	1.41 (0.82-2.43)	0.62 (0.26-1.45)	0.50 (0.28-0.90)
5-9 years	0.65 (0.18-2.41)	0.97 (0.34-2.74)	1.46 (0.88-2.41)	0.95 (0.52-1.75)	0.72 (0.47-1.09)
10-14 years	1.23 (0.46-3.29)	1.36 (0.54-3.43)	0.95 (0.59-1.53)	1.04 (0.64-1.68)	0.90 (0.66-1.24)
15-18 years	1.0 (Ref)	1.0 (Ref)	1.0 (Ref)	1.0 (Ref)	1.0 (Ref)
Sex					
Female	1.37 (0.61-3.06)	0.88 (0.44-1.75)	1.04 (0.71-1.52)	1.12 (0.73-1.73)	1.06 (0.80-1.40)
Male	1.0 (Ref)	1.0 (Ref)	1.0 (Ref)	1.0 (Ref)	1.0 (Ref)
Race/Ethnicity					
Black	0.59 (0.23-1.54)	0.41 (0.09-1.83)	1.71 (1.03-2.84)	1.31 (0.80-2.14)	1.59 (1.08-2.34)
Hispanic	1.21 (0.37-3.93)	1.53 (0.70-3.37)	2.82 (1.81-4.38)	1.76 (1.03-3.00)	2.37 (1.69-3.33)
Other	0.54 (0.07-4.36)	1.25 (0.41-3.81)	2.59 (1.36-4.92)	0.25 (0.04-1.80)	2.14 (1.35-3.40)
White	1.0 (Ref)	1.0 (Ref)	1.0 (Ref) ^a	1.0 (Ref)	1.0 (Ref) ^a

452

453 ^aIndicates *P* value < 0.0001 for race/ethnicity in the statistical model.

454 Statistically significant values are shown in bold text.

455 **Supplemental table 1. Co-morbidities of sampled populations in Arkansas during 5 periods of SARS-CoV-2 antibody testing from April**
 456 **2, 2020 to April 29, 2021.**

Number (%) ^a						
Characteristic	Wave 1 (n = 316)	Wave 2 (n = 300)	Wave 3 (n = 594)	Wave 4 (n = 600)	Wave 5 (n = 590)	Overall (N = 2400)
Collection dates	April 2 – May 6, 2020	June 6 – August 10, 2020	September 8 – October 17, 2020	November 7 – December 17, 2020	April 5 – April 28, 2021	April 2, 2020 – April 28, 2021
Respiratory viral panel within 6 mo.	NR	34 (11.3)	35 (5.9)	25 (4.2)	NR	94 (6.3)
Asthma	12 (3.8)	31 (10.3)	68 (11.5)	62 (10.4)	66 (11.2)	239 (10.0)
Hypertension	16 (5.1)	16 (5.3)	25 (4.2)	34 (5.7)	20 (3.4)	111 (4.6)
Obesity	14 (4.4)	46 (15.3)	83 (14.0)	109 (18.3)	85 (14.4)	337 (14.1)
Diabetes	10 (3.2)	15 (5.0)	30 (5.1)	27 (4.5)	31 (5.3)	113 (4.7)
Autoimmune disease	NR	7 (2.3)	14 (2.4)	19 (3.2)	23 (3.9)	63 (3.0)

457

458 ^a Percentages calculated from non-missing values for all periods. Missing values in Wave 1 included respiratory virus panel performed within 6 months (n = 316) and autoimmune disease (n = 316),
 459 Missing values in Wave 4 included respiratory virus panel performed within 6 months (n = 5), asthma (n = 5), hypertension (n = 5), obesity (n = 5), diabetes (n = 5), and autoimmune disease (n
 460 = 5). Missing values in Wave 5 included Respiratory viral panel within 6 months (n = 590).

461 NR = not reported

Supplemental table 2. Marginal association between SARS-CoV-2 antibody positivity and demographic characteristics by time period.

Wave number	Characteristic ^a	Age category				Sex		Race/ethnicity				Metropolitan status	
		1-4 years	5-9 years	10-14 years	15-18 years	Female	Male	Black	Hispanic	Others	White	Urban	Rural
Wave 1 (n = 316)	No., (%)	6 (10.7)	3 (4.9)	8 (8.9)	8 (7.3)	14 (8.7)	11 (7.1)	5 (5.5)	3 (10.7)	1 (5.6)	16 (9.0)	NR	NR
	RR (95% CI)	1.46 (0.53-4.00)	0.67 (0.18-2.43)	1.21 (0.47-3.10)	1.0 (Ref)	1.23 (0.57, 2.62)	NC	0.61 (0.23-1.62)	1.19 (0.37-3.83)	0.62 (0.09-4.39)	1.0 (Ref)	NC	NC
	P-value ^b	0.690				0.600		0.706				NC	
Wave 2 (n = 300)	No., (%)	5 (15.2)	6 (8.0)	11 (11.2)	7 (7.5)	14 (9.0)	15 (10.3)	2 (3.8)	9 (14.1)	3 (12.5)	15 (9.7)	28 (11.2)	1 (2.0)
	RR (95% CI)	2.03 (0.69-5.97)	1.07 (0.38-3.06)	1.51 (0.61-3.72)	1.0 (Ref)	0.87 (0.44, 1.74)	1.0 (Ref)	0.39 (0.09-1.64)	1.44 (0.67-3.13)	1.28 (0.40-4.10)	1.0 (Ref)	5.47 (0.76-39.24)	1.0 (Ref)
	P-value ^b	0.539				0.701		0.352				0.091	
Wave 3 (n = 594)	No., (%)	16 (19.8)	21 (18.8)	29 (14.2)	30 (15.3)	56 (17.3)	40 (14.8)	20 (17.1)	28 (29.5)	9 (27.3)	35 (10.7)	76 (16.6)	20 (14.7)
	RR (95% CI)	1.29 (0.75-2.23)	1.23 (0.74-2.03)	0.92 (0.58-1.48)	1.0 (Ref)	1.17 (0.80-1.69)	1.0 (Ref)	1.60 (0.96-2.65)	2.75 (1.77-4.28)	2.55 (1.34-4.83)	1.0 (Ref)	1.13 (0.72-1.78)	1.0 (Ref)
	P-value ^b	0.560				0.417		<0.0001				0.602	
Wave 4 (n = 600)	No., (%)	6 (7.2)	15 (12.9)	30 (14.0)	27 (14.8)	46 (13.6)	32 (12.5)	23 (15.3)	16 (20.8)	1 (2.9)	36 (11.5)	55 (13.0)	23 (13.5)
	RR (95% CI)	0.49 (0.21-1.14)	0.87 (0.48-1.57)	0.95 (0.58-1.53)	1.0 (Ref)	1.09 (0.72-1.67)	1.0 (Ref)	1.33 (0.82-2.16)	1.80 (1.06-3.07)	0.25 (0.04-1.80)	1.0 (Ref)	0.96 (0.61-1.52)	1.0 (Ref)
	P-value ^b	0.410				0.679		0.060				0.876	
Wave 5 (n = 590)	No., (%)	12 (16.0)	27 (19.0)	58 (30.9)	54 (29.5)	90 (27.0)	61 (23.9)	31 (28.4)	38 (43.7)	15 (35.7)	57 (17.9)	101 (23.4)	50 (31.9)
	RR (95% CI)	0.54 (0.31-0.95)	0.64 (0.43-0.97)	1.05 (0.77-1.43)	1.0 (Ref)	1.13 (0.85-1.50)	1.0 (Ref)	1.59 (1.09-2.32)	2.44 (1.74-3.41)	1.99 (1.25-3.18)	1.0 (Ref)	0.74 (0.55-0.98)	1.0 (Ref)
	P-value ^b	0.018				0.395		<0.0001				0.035	

464 ^aMissing values from Supplemental table 1 were not included in the analysis.

465 ^bP-value indicates whether the positivity differs between the category of a respective variable.

466 Statistically significant values are shown in bold text.

Supplemental table 3. Marginal association between SARS-CoV-2 antibody positivity and comorbidities by time period.

Wave number	Characteristic ^a	Respiratory virus panel within 6 months		Asthma		Hypertension		Obesity		Diabetes		Autoimmune disease	
		Yes	No	Yes	No	Yes	No	Yes	No	Yes	No	Yes	No
Wave 1 (n = 316)	No., (%)	NR	NR	4 (33.3)	21 (6.9)	0	25 (8.3)	1 (7.1)	24 (8.0)	3 (30.0)	22 (7.2)	NR	NR
	RR (95% CI)	ND	ND	4.83 (1.96-11.87)	1.0 (Ref)	ND	ND	0.90 (0.13-6.18)	1.0 (Ref)	4.17 (1.49-11.67)	1.0 (Ref)	ND	ND
	P-value ^b	ND		0.003		ND		0.914		0.007		ND	
Wave 2 (n = 300)	No., (%)	6 (17.7)	23 (8.7)	5 (16.1)	24 (8.9)	1 (6.3)	28 (9.9)	5 (10.9)	24 (9.5)	0 (0.0)	29 (10.2)	1 (14.3)	28 (9.6)
	RR (95% CI)	2.04 (0.89-4.65)	1.0 (Ref)	1.81 (0.74-4.40)	1.0 (Ref)	0.63 (0.09-4.37)	1.0 (Ref)	1.15 (0.46-2.86)	1.0 (Ref)	NC	1.0 (Ref)	1.49 (0.24-9.49)	1.0 (Ref)
	P-value ^b	0.090		0.192		0.643		0.763		NC		0.670	
Wave 3 (n = 594)	No., (%)	7 (20.0)	89 (15.9)	6 (8.8)	90 (17.1)	6 (24.0)	90 (15.8)	15 (18.1)	81 (15.9)	5 (16.7)	91 (16.1)	2 (14.3)	94 (16.2)
	RR (95% CI)	1.26 (0.63-2.50)	1.0 (Ref)	0.52 (0.23-1.13)	1.0 (Ref)	1.52 (0.74-3.13)	1.0 (Ref)	1.14 (0.69-1.88)	1.0 (Ref)	1.03 (0.45-2.35)	1.0 (Ref)	0.88 (0.24-3.22)	1.0 (Ref)
	P-value ^b	0.517		0.099		0.258		0.607		0.938		0.849	
Wave 4 (n = 600)	No., (%)	0 (0.0)	78 (13.7)	5 (8.1)	73 (13.7)	5 (14.7)	73 (13.0)	16 (14.7)	62 (12.8)	2 (7.4)	76 (13.4)	2 (10.5)	76 (13.2)
	RR (95% CI)	ND	ND	0.59 (0.25-1.40)	1.0 (Ref)	1.13 (0.49-2.61)	1.0 (Ref)	1.15 (0.69-1.91)	1.0 (Ref)	0.55 (0.14-2.14)	1.0 (Ref)	0.80 (0.21-3.01)	1.0 (Ref)
	P-value ^b	ND		0.231		0.775		0.589		0.391		0.739	
Wave 5 (n = 590)	No., (%)	NR	NR	16 (24.2)	136 (26.0)	7 (35.0)	145 (25.4)	20 (23.5)	132 (26.1)	12 (38.7)	140 (25.0)	7 (30.4)	145 (25.6)
	RR (95% CI)	ND	ND	0.93 (0.60-1.47)	1.0 (Ref)	1.38 (0.74-2.54)	1.0 (Ref)	0.90 (0.60-1.36)	1.0 (Ref)	1.55 (0.97-2.46)	1.0 (Ref)	1.19 (0.63-2.24)	1.0 (Ref)
	P-value ^b	ND		0.767		0.308		0.616		0.067		0.590	

468

469 ^aMissing values from Supplemental table 1 were not included in the analysis.470 ^bP-value indicates whether the positivity differs between the category of a respective variable.

471 Statistically significant values are shown in bold text.

472 NR = not reported; ND = not determined

473 **Supplemental table 4. PCR test history and results from sampled populations in Arkansas during 5 periods of SARS-CoV-2 antibody**
 474 **testing from April 2, 2020 to April 28, 2021.**

Number (%) ^a						
Characteristic	Wave 1 (n = 316)	Wave 2 (n = 300)	Wave 3 (n = 594)	Wave 4 (n = 600)	Wave 5 (n = 590)	Overall (N = 2400)
Collection dates	April 2 – May 6, 2020	June 6 – August 10, 2020	September 8 – October 17, 2020	November 7 – December 17, 2020	April 5 – April 28, 2021	April 2, 2020 – April 28, 2021
SARS-CoV-2 RT-PCR test administered						
Yes	64 (20.3)	82 (27.3)	160 (26.9)	173 (29.1)	235 (39.8)	714 (29.8)
No	252 (79.7)	218 (72.7)	434 (73.1)	422 (70.9)	355 (60.2)	1681 (70.2)
SARS-CoV-2 RT-PCR test result						
Positive	0 (0.0)	1 (1.2)	6 (3.8)	11 (6.4)	20 (8.6)	38 (5.3)
Negative	64 (100)	81 (98.8)	154 (96.2)	162 (93.6)	214 (91.5)	675 (94.7)

475

476

477


478

^a Percentages calculated from non-missing values for all periods. Missing values in Wave 1 included SARS-CoV-2 RT-PCR test result (n = 252). Missing values in Wave 2 included SARS-CoV-2 RT-PCR test result (n = 218). Missing values in Wave 3 included SARS-CoV-2 RT-PCR test result (n = 434). Missing values in Wave 4 included SARS-CoV-2 RT-PCR test administered (n = 5) and SARS-CoV-2 RT-PCR test result (n = 427). Missing values in Wave 5 included SARS-CoV-2 PCR test result (n = 356).

479 **Supplemental table 5. Marginal association between SARS-CoV-2 antibody positivity and SARS-CoV-2 PCR testing by time period.**
 480 **RT-PCR testing by time period.**
 481

Wave number	Characteristic ^a	COVID-19 test administered		COVID-19 PCR result	
		Yes	No	Positive	Negative
Wave 1 (n = 316)	No., (%)	4 (6.3)	21 (8.3)	0 (0.0)	4 (6.3)
	RR (95% CI)	0.75 (0.27-2.11)	1.0 (Ref)	ND	ND
	P-value ^b	0.585		NA	
Wave 2 (n = 300)	No., (%)	11 (13.4)	18 (8.3)	1 (100)	10 (12.4)
	RR (95% CI)	1.62 (0.80-3.29)	1.0 (Ref)	8.10 (4.53-14.47)	1.0 (Ref)
	P-value ^b	0.178		<0.0001	
Wave 3 (n = 594)	No., (%)	28 (17.5)	68 (15.7)	4 (66.7)	24 (15.6)
	RR (95% CI)	1.12 (0.75-1.67)	1.0 (Ref)	4.28 (2.18-8.40)	1.0 (Ref)
	P-value ^b	0.589		<0.0001	
Wave 4 (n = 600)	No., (%)	21 (12.1)	57 (13.5)	8 (72.7)	13 (8.0)
	RR (95% CI)	0.90 (0.56-1.44)	1.0 (Ref)	9.06 (4.80-17.10)	1.0 (Ref)
	P-value ^b	0.655		<0.0001	
Wave 5 (n = 590)	No., (%)	57 (24.3)	95 (26.8)	17 (85.0)	40 (18.7)
	RR (95% CI)	0.91 (0.68-1.20)	1.0 (Ref)	4.55 (3.25-6.35)	1.0 (Ref)
	P-value ^b	0.498		<0.0001	

482
 483 ^aMissing values from Table 1 were not included in the analysis.
 484 ^bP-value indicates whether the positivity differs between the category of a respective variable.
 485 Statistically significant values are shown in bold text.
 486 ND = not determined






Figure 2